In ABC-DLBCL, JAK1/STAT3 was activated by autocrine IL-6/10 signaling, and Ruxolitinib synergized well with type I IFN inducer lenalidomide in vitro and in vivo [142]. This evidence concerns the gene IL6 and diffuse large B-cell lymphoma.